Goldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target

Goldman Sachs analyst Andrea Newkirk has reinstated a Buy rating on Tarsus Pharmaceuticals (NASDAQ: TARS) and set a price target of $116 for the stock. This strategic move indicates confidence in the company's future performance.